In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
The evolving vaccine landscape: Insights from the 6th ESCMID Conference on Vaccines
The conference brought together the vaccine community and stakeholders, including industry representatives, clinicians, regulators, policymakers, academics,...